AI assistant
Immuron Ltd Regulatory Filings 2006
35121_rns_2006-02-01_7056bffb-2b2d-485b-838c-82d4563c44b1.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
February 2nd, 2006
Company Announcement Office Australian Stock Exchange Ltd (ASX) 4th Floor, 20 Bridge Street Sydney NSW 2000
Dear Sir/Madam
Please find herewith a company announcement "Travelan Safe for International Athletes" for release and distribution to the market immediately.
Yours sincerely
CONOR GRAHAM Managing Director & CEO
Travelan* Safe for International Athletes
Anadis Limited is pleased to announce that Travelan has successfully been analysed by the Australian Government Analytical Laboratory, an IOC (International Olympic Committee) accredited laboratory. This analysis confirmed that Travelan does not contain any prohibited substances, as defined by the World Anti-Doping Code 2006 Prohibited List. Anadis can now issue written guarantees for the use of Travelan® by athletes - for the prevention of travellers' diarrhoea - when used in accordance with the directions on the pack and product leaflet.
Anadis will now actively pursue an international market of high profile sporting organisations, including those preparing for competition in the Beijing Olympics during 2008.
Travellers' diarrhoea (TD) is the number one health problem for international travellers, with implications not only for the IOC and individual member countries official's and athlete's whose personal trip is ruined by "Bali Belly etc" but for anyone who cannot risk being disabled by stomach cramps, bloating, nausea, dehydration and diarrhoea when travelling.
Travellers' diarrhoea can potentially lead to many hours of lost time, withdrawal from events and of course significantly impact overall performance. Travellers' diarrhoea can also impact sporting organisations and agencies when their athletes and administrators are stricken – with potentially significant losses.
Travelan - Natural and Effective
Travelan, a natural, clinically proven therapy is prepared from bovine colostrum from cows hyper-immunized against the 13 strains of E. coli that are the most common cause of travellers' diarrhoea. Travelan is high in antibodies that bind to certain intestinal bacteria and bacterial by-products, and is non-antibiotic preparation therefore not associated with the usual negative antibiotic side effects.
Travelan is a natural product that will enable athletes and administrators (and of course the general public) to travel with reduced fear of becoming ill due to exposure to E.coli bacteria. In hospital clinical trials in the US and Europe, Travelan® has shown up to 90% protection against Enterotoxigenic E. coli (ETEC), the main cause of Travellers' Diarrhoea.
Potential Additional Gastrointestinal Indications for Travelan
Anadis is now investigating the use of Travelan for additional gastrointestinal therapeutic indications as a result of positive clinical feedback from a number of healthcare providers including medical specialists.
Reports to the company indicate that a number of patients with a range of gastrointestinal conditions, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and ulcerative colitis, have experienced an improvement in some of their symptoms (e.g. diarrhoea) whilst taking Travelan to reduce their risk of travellers' diarrhoea.
International opportunities for Travelan
Anadis has recently been given a "green light" to sell Travelan in the US (see announcement Travelan receives Green Light to enter US market - 12th October 2005). and is currently in discussions with prospective partners in the US market to begin sales of Travelan at the earliest opportunity.
Anadis has appointed Baralex Inc. / Valeo Pharma as Canadian pharmaceutical distributor for Travelan. Registration and the distribution agreement and are set for completion in late January 2006. First sales of Travelan into the Canadian market anticipated to begin February / March 2006.
Anadis is in the process of negotiating other international distribution and registration arrangements in markets including Singapore, Hong Kong, India, Thailand, Taiwan, Malaysia, United Kingdom, Europe and South Africa.
For more information about Travelan visit www.travelan.com.au
About Anadis Limited:
Anadis, a Melbourne based Biopharmaceutical Company, focused on Nutraceutical and Pharmaceutical product development. Anadis is currently also in the process of commercialising $EV-71$ - a bioactive protein based product against Enterovirus 71, a debilitating polio like disease affecting children in Taiwan and other parts of Asia.
A set of Bio-Defence/Respiratory Protection technologies where it has been shown that Anthrax lethal toxin can be 100% neutralized by Anadis' bovine colostrum derived antibodies. This project in conjunction with the Australian Department of Defence and US Bio-Defence Organisations, initially focused on short-term immediate protection from airborne bacteria such as Anthrax and Plague, future civilian applications include Hav Fever and Asthma.
Bio-Shield 10 a range of "bioshielding" technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market, and research has also begun into an Immune Stimulating Infant Formula initially for the Asian market.
Pyloran, which has been clinically proven to reduce levels of bacteria in the stomach and reduce the symptoms of H.pylori associated gastritis - Anadis is also in early development of a H.pvlori vaccine.
For further information, please contact:
Conor Graham - Chief Executive Officer Email: [email protected] $+61393586388$
David Lyon - Sales & Marketing Manager
Email david. [email protected] $+61393586388$
Arie Nudel – Investor Relations
Email: [email protected] $+61393586388$
Visit our websites: www.anadis.com.au and www.travelan.com.au